UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
CLL Therapy in 2020 - Ibrutinib+ Rituximab Provides Superior PFS and OS, Fixed Duration Venetoclax/Obinutuzumab, Acalabrutinib Safe and Effective
Login to view comments.
Click here to Login